Artemisone - Artemis Therapeutics

Drug Profile

Artemisone - Artemis Therapeutics

Alternative Names: BAY-44-9585

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer; Medicines for Malaria Venture
  • Developer Artemis Therapeutics; Bayer; Hong Kong University of Science and Technology
  • Class Antimalarials
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malaria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Malaria
  • Preclinical Cytomegalovirus infections

Most Recent Events

  • 28 Nov 2017 Artemis Therapeutics has patent protection for Artemisone in European Union
  • 06 Nov 2017 Artemisone - Artemis Therapeutics receives Orphan Drug status for Malaria treatment in USA
  • 30 May 2017 Phase-I clinical trials in Malaria treatment in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top